Mavefund EN
Cronos Group Inc logo

Cronos Group Inc

CRON
Letzter Kurs (USD) US$3.35
Marktkapitalisierung (USD) US$1.2b
Kursänderung 12 Monate 28.85%
Loading the 12-month Mave Thesis and 1-month news signal

Branchen- und Sektorvergleich sowie weitere Research-Alternativen

Vergleich ansehen
Zoetis IncZTS Vergleich Amphastar PAMPH Vergleich Prestige Consumer HealthcarePBH Vergleich IQVIA Holdings IncIQV Vergleich
Überblick Ergebnisbericht Kursverlauf Nachrichten Wettbewerber Gewinn je Aktie Eigenkapitalrendite Nettomarge Aktienrückkäufe Verschuldung Finanzberichte Finanzkennzahlen
Start Heute Aktien Watchlist

Cronos Group Inc Überblick

Branche: Drug Manufacturers Specialty & Generic

Sektor: Healthcare

Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, edibles, concentrates, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under adult-use brands, Spinach. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada. Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones brand in the United States. The company is also involved in the cultivation,

Research-Überblick

Letztes Berichtsdatum 2026-08-06

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Cronos Group Inc (CRON): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
CRON · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Drug Manufacturers Specialty & Generic
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-06
Primärquellen

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Cronos Group Inc für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 06, 2026

Quarterly result summary

Revenue was $53M (reported). Operating income was $7.4M (-239% YoY). Net income was $35.7M (-7% YoY).

Revenue $53M reported
Operating income $7.4M -239% YoY
Net income $35.7M -7% YoY
Adjusted EBITDA $13.1M reported

Was sich verändert hat

  • Revenue reported to $53M.
  • Operating income -239% YoY to $7.4M.
  • Net income -7% YoY to $35.7M.

Guidance / outlook

The Company expects the acquisition to close in the second half of 2026. We have not been informed of any specific issues with our regulatory clearance submission, and based on the information available to us, the timing appears to reflect the ordinary course of the Dutch regulatory review process for a transaction of this nature.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen
SEC filing 10-Q Aug 06, 2026 SEC filing 8-K Aug 06, 2026 SEC filing 10-Q May 11, 2026 Earnings release Earnings release May 11, 2026 SEC filing 10-K Feb 26, 2026 SEC filing 8-K Feb 26, 2026 Earnings release Earnings release Feb 26, 2026 SEC filing 10-Q Nov 06, 2025 SEC filing 8-K Nov 06, 2025 Earnings release Earnings release Nov 06, 2025 SEC filing 8-K Aug 07, 2025

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 3.00/5
Cronos Group Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Eigenkapitalrendite

Score 2.14/5
Cronos Group Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Cronos Group... CRON US$1.2b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Nettomarge

Score 1.48/5
Cronos Group Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Cronos Group... CRON US$1.2b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Aktienrückkäufe

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Verschuldung

Score 4.10/5
Cronos Group Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
Cronos Group... CRON US$1.2b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Cronos Group Inc logo

Cronos Group Inc

US$3.35

US$2.20

-34.8% vs price

US$1.2b

-2.19%

28.85%